{"id":2711,"date":"2023-12-05T02:11:27","date_gmt":"2023-12-05T02:11:27","guid":{"rendered":"https:\/\/economicherald.net\/?p=2711"},"modified":"2023-12-05T02:11:27","modified_gmt":"2023-12-05T02:11:27","slug":"asx-health-stocks-neuren-pharma-to-begin-phase-2-clinical-trial-of-children-with-pitt-hopkins-syndrome","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=2711","title":{"rendered":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome"},"content":{"rendered":"<p>Neuren Pharma completes Phase 2 patient enrolment<br \/>\nCyclopharm signed a deal with globally respected Duke University Hospital<\/p>\n<p>\u00a0<\/p>\n<h2>Neuren\u2019s Phase 2 Pitt Hopkins syndrome clinical trial<\/h2>\n<p>Market darling<strong> <a href=\"https:\/\/stockhead.com.au\/company\/neuren-pharmaceuticals-neu\/\">Neuren Pharmaceuticals (ASX:NEU)<\/a><\/strong> announced that enrolment of subjects into its <strong>Phase 2 clinical trial of NNZ-2591<\/strong> in <strong>Pitt Hopkins syndrome<\/strong> has been completed.<\/p>\n<p>Top-line results from the trial are expected to be available in Q2 2024.<\/p>\n<p>The Phase 2 trial in children aged 3 to 17 years at five hospitals in the US will examine the safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591.<\/p>\n<p>All subjects will receive NNZ-2591 as an oral liquid dose twice daily.<\/p>\n<p>Pitt Hopkins syndrome (PTHS) is a neuro-developmental condition caused by the loss of one copy or a mutation of the TCF4 gene on chromosome 18. The incidence of PTHS has been estimated at between 1 in 34,000 and 1 in 41,000 people. Some individuals with PTHS are diagnosed with autism.<\/p>\n<p>Neuren is also conducting Phase 2 clinical trials of <strong>NNZ-2591<\/strong> in children with three other neurodevelopmental disorders \u2013 <strong>Phelan McDermid syndrome,<\/strong> <strong>Angelman syndrome<\/strong> and <strong>Prader-Willi syndrome<\/strong>.<\/p>\n<p>All four programs have been granted <strong>Orphan Drug designation by the US FDA<\/strong>, and are being developed under Investigational New Drug (IND) applications.<\/p>\n<p>The company says that each syndrome is a seriously debilitating neurological disorder that emerges in early childhood, and has no or limited approved treatment options.<\/p>\n<p>\u201cWe are grateful to all the people who have contributed to achieving this important milestone as we strive to develop a potential first therapy for Pitt Hopkins syndrome, including the Pitt Hopkins community and the trial site teams in the United States,\u201d says Neuren CEO, Jon Pilcher.<\/p>\n<p>\u201cWe now look forward to the remaining patients completing the trial, and to releasing the first results of treatment with NNZ-2591 in children with Pitt Hopkins syndrome.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Cyclopharm signs deal with Duke University Hospital<\/h2>\n<p>Meanwhile, radiopharmaceutical specialist, <strong><a href=\"https:\/\/stockhead.com.au\/company\/cyclopharm-cyc\/\">Cyclopharm (ASX:CYC)<\/a><\/strong>, announced that <strong>Duke University Hospital<\/strong> has signed the first commercial contract for the use of <strong>Cyclopharm\u2019s Technegas<\/strong> product in the US.<\/p>\n<p>This agreement follows the approval of Technegas by the US FDA in September.<\/p>\n<p>Duke University Hospital is located in Durham, North Carolina, and is part of the larger Duke University Health System. It is a renowned academic medical centre known for its high-quality patient care, research and medical education.<\/p>\n<p>Duke University Hospital is also consistently ranked among the top medical centres in the US, offering a wide range of specialties.<\/p>\n<p>The hospital was one of 10 locations in the US that participated in Cyclopharm\u2019s recent clinical trial that was submitted as part of the New Drug Application (NDA) for Technegas.<\/p>\n<p>\u201cI am thrilled that Duke University Hospital, a globally respected centre of healthcare excellence, innovation and a recent clinical trial site for Technegas, will be among the first to offer Technegas to their referring physicians and patients,\u201d said Cyclopharm\u2019s CEO, James McBrayer.<\/p>\n<p>\u201cThe implementation of Technegas at Duke will be on full commercial terms as previously communicated to the market, and will be leveraging off Technegas\u2019 wide indication for use approved by the US FDA.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Neuren and Cylcopharm share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span><br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-neuren-pharma-to-begin-phase-2-clinical-trial-of-children-with-pitt-hopkins-syndrome\/\">ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Neuren Pharma completes Phase 2 patient enrolment Cyclopharm signed a deal with globally respected Duke University Hospital \u00a0 Neuren\u2019s Phase 2 Pitt Hopkins syndrome clinical <a href=\"https:\/\/economicherald.net\/?p=2711\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":2712,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=2711\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Neuren Pharma completes Phase 2 patient enrolment Cyclopharm signed a deal with globally respected Duke University Hospital \u00a0 Neuren\u2019s Phase 2 Pitt Hopkins syndrome clinical [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=2711\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T02:11:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome\",\"datePublished\":\"2023-12-05T02:11:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711\"},\"wordCount\":547,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2711#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=2711\",\"name\":\"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg\",\"datePublished\":\"2023-12-05T02:11:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2711\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2711#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=2711","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald","og_description":"Neuren Pharma completes Phase 2 patient enrolment Cyclopharm signed a deal with globally respected Duke University Hospital \u00a0 Neuren\u2019s Phase 2 Pitt Hopkins syndrome clinical [more...]","og_url":"https:\/\/economicherald.net\/?p=2711","og_site_name":"Economic Herald","article_published_time":"2023-12-05T02:11:27+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=2711#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=2711"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome","datePublished":"2023-12-05T02:11:27+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=2711"},"wordCount":547,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=2711#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=2711#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=2711","url":"https:\/\/economicherald.net\/?p=2711","name":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=2711#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=2711#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg","datePublished":"2023-12-05T02:11:27+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=2711#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=2711"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=2711#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Neuren-Pharma-completes-Phase-2-patient-enrolment.-Picture-Getty-B5exVo.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=2711#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2711"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2711\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/2712"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}